Lovastatin Tablet
Product Images NDC 70518-3064

4 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 70518-3064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lovastatin 40mg 70518 3064 01

Lovastatin 40mg 70518 3064 01
Lovastatin 40 mg oral tablet label indicating a quantity of 30 tablets. The label includes the brand name 'Lovastatin' and states 'RX ONLY.' The manufacturer is listed as Teva from Frazer, PA. Repackaged by RemedyRepack Inc., Indiana, PA. Additional storage and usage directions refer to the package insert.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Lovastatin 40 mg oral tablet packaging label showing a quantity of 90 tablets. The label includes the manufacturer information, indicating repackaging by RemedyRepack Inc., Indiana, PA, and mentions the original manufacturer as Teva, Frazer, PA. The label also contains storage directions and a QR code.*
FDA Label Image

Lovastatin Structural Formula (Image 1)

Lovastatin Structural Formula (Image 1)
Chemical structure diagram showing the molecular composition of Lovastatin, the active ingredient in the product. The diagram includes labeled atoms and bonds illustrating the structure of Lovastatin.*
FDA Label Image

Figure 1: Actue Major Coronary Events (primary Endpoint) (Image 2)

Figure 1: Actue Major Coronary Events (primary Endpoint) (Image 2)
A line chart titled 'Acute Major Coronary Events (Primary Endpoint)' comparing the proportion of participants without events over six years of follow-up between Lovastatin and placebo groups. The Lovastatin line shows fewer events, indicating a 37% risk reduction versus placebo (p < 0.001). The y-axis represents the proportion of participants without events (from 0.90 to 1.00), and the x-axis shows years of follow-up (0 to 6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.